Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Boadilla del Monte, Spain Clinical Trials

A listing of Boadilla del Monte, Spain clinical trials actively recruiting patients volunteers.

Found (97) clinical trials

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

The primary objective of this study is to investigate the efficacy of larotrectinib for the treatment of advanced solid tumors harboring a fusion of neurotrophic tyrosine receptor kinase (NTRK) of types 1-3 in children and adults. Secondary objectives comprise the efficacy and safety of larotrectinib in different NTRK-tumor types.

Phase

8.27 miles

Learn More »

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving INC280 Treatment as Single Agent or in Combination With Other Treatments.

The rollover study will provide continued treatment and assessment of long-term safety follow-up in patients receiving capmatinib (INC280) as a single agent or in combination with EGF816 or Gefitinib in a Novartis sponsored study and in the opinion of the Investigator would benefit from continued treatment.

Phase

8.27 miles

Learn More »

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

LN-144 (Lifileucel)/LN-145/LN-145-S1 is an adoptive cell transfer therapy that utilizes an autologous TIL manufacturing process for the treatment of patients with advanced unresectable or metastatic melanoma, advanced squamous cell carcinoma of the head and neck, and non-small cell lung cancer. The adoptive cell transfer therapy used in this study involves …

Phase

8.27 miles

Learn More »

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Avelumab is a human immunoglobulin (Ig)G1 monoclonal antibody (mAb) directed against programmed death ligand 1 (PD-L1). Avelumab selectively binds to PD-L1 and competitively blocks its interaction with programmed death receptor 1 (PD-1), thereby interfering with this key immune checkpoint inhibition pathway. Avelumab is currently being investigated as single agent and …

Phase

8.27 miles

Learn More »

Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation

The purpose of this Phase IIa/IIb dose ranging study is to generate human data in the intended patient population with IgAN to establish clinical proof-of-concept and to evaluate dose responses to support dose selection for subsequent clinical development of LNP023 for IgAN and potentially other indications

Phase

8.27 miles

Learn More »

Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-na ve Patients With Asymptomatic Brain Metastasis

Atezolizumab will be administered intravenously (iv) at a dose of 1200 mg over 60 minutes on day 1 of each cycle. The subsequent cycles of atezolizumab can be administered over 30 minutes, if there were no infusion-related toxicities. Pemetrexed will be administered at a dose of 500 mg/m2 iv over …

Phase

8.27 miles

Learn More »

Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.

- To determine the 1-year rate of locoregional disease control in the experimental arm, using a control arm to avoid selection bias. - To determine the 2 and 3 year rate of locoregional disease control. - To evaluate the safety and toxicity of the combination of cetuximab and concomitant-boost accelerated …

Phase

8.27 miles

Learn More »

Study of 3D Radiotherapy With or Without Erlotinib (Tarceva ) in Patients With Localized Non-Small Cell Lung Cancer

A phase II, multicenter, randomized trial of 3D Radiotherapy versus 3D Radiotherapy and erlotinib (Tarceva®) in patients with localized-unresectable (IA-IIIB) non-small cell lung cancer non susceptible for chemotherapy treatment, to compare safety and toxicity profile, and the progression-free survival in both arms of treatment (3D Radiotherapy versus 3D Radiotherapy + …

Phase

8.27 miles

Learn More »

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

This is a Phase 1b/2, open label, multicenter, safety, clinical activity, pharmacokinetic (PK), and pharmacodynamics (PD) study of avelumab in combination with chemotherapy with or without other anti-cancer immunotherapies, as first-line treatment of adult patients with locally advanced or metastatic solid tumors. Initially, avelumab will be evaluated in combination with …

Phase

8.27 miles

Learn More »

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

This is an open-label, multi-center, single arm, phase II study to assess the anti-tumor activity and safety of bemcentinib when given in combination with pembrolizumab in up to 77 patients with previously treated, advanced adenocarcinoma of the lung. The study will enroll two cohorts of patients with previously treated, advanced …

Phase

8.27 miles

Learn More »